Eagle Pharmaceuticals has acquired Arsia Therapeutics, an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how. The acquisition will mark Eagle’s entry into biologics, the fastest growing sector of the pharmaceuticals market, and will allow the company to apply its strategy to offer “biobetter” formulations, and to aid in the development of novel biologics. “Arsia will significantly enhance Eagle’s formulation capabilities and greatly expand o...